Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
If you have Triple Negative Breast Cancer:
- Your breast cancer must test negative for estrogen receptors, progesterone receptors, and HER2 (a specific type called "triple negative")
- Your cancer can be at any stage (Stage I through Stage IV)
- You can be any age when you were diagnosed
- You must have been diagnosed within the last 5 years
- You can join whether or not you have had genetic testing done
- Genetic testing is recommended if you meet certain guidelines (confirm with trial site)
And/Or if you carry a gene mutation linked to hereditary cancer:
- You carry a harmful or uncertain gene mutation linked to hereditary breast and ovarian cancer (such as BRCA, PTEN, P53, PALB2, or similar genes)
- You can have any type of cancer, not just breast cancer
- You can join even if you are healthy and have never had cancer
- There is no time limit between your cancer diagnosis and joining the trial
- You can join regardless of your personal history of cancer
Who may not be able to join:
- People with Triple Negative Breast Cancer who were diagnosed more than 5 years ago
- People whose only gene mutation has been classified as a normal variation ("polymorphism" or "favor polymorphism") rather than a harmful mutation
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Priyanka Sharma, MD, University of Kansas Medical Center
Phone: 913-588-8548
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prevalence of germline mutations (such as BRCA1/2 mutations) in patients with TNBC; . Predictors of response to neo/adjuvant chemotherapy in patients with TNBC; Long term Disease free and overall survival rates in TNBC patients treated with different systemic therapies
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.